ABL1 Gene Editing


Our promise to you:
Guaranteed product quality, expert customer support.


ABL1 Gene Editing    

ABL1 (Abelson murine leukemia viral oncogene homolog 1) belongs to a non-receptor tyrosine kinase. And the ABL1 gene belongs to the primary oncogene and is located on human chromosome 9. c-ABL is sometimes used to refer to the version of the gene found in the mammalian genome, while v-ABL refers to the viral gene. The study on ABL mainly focuses on BCR-ABL, a constitutively activated oncogenic tyrosine kinase in human chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphocytes.

Structurally, the conserved ABL protein structure comprises the N-terminal with SH3, SH2, and the kinase domain and the actin binding domain (ABD) at C-terminal (Figure 1).

Domain structure of ABL-family kinases Figure 1: Domain structure of ABL-family kinases (William D. 2009)

Functionally, in response to growth factors, cytokines, cell adhesion, DNA damage, oxidative stress, and other signals, ABL is activated to stimulate cell proliferation or differentiation, survival or death, retraction or migration. ABL also regulates specialized functions such as antigen receptor signaling in lymphocytes, synapse formation in neurons, and adhesion of bacteria to intestinal epithelial cells. Recent studies have shown that ABL kinase is activated in neurodegenerative diseases such as Parkinson's disease. And ABL is found to phosphorylate Parkin to inhibit its E3-ubiquitin ligase function.

Since ABL regulates many aspects of biology associated with human diseases, from cancer to neuronal degeneration, the mechanism of action of ABL1 in a defined biological context also requires further substitution. Using mutant animal models, FDA-approved inhibitors, and cancer patients with long-term exposure to these drugs, researchers can well target ABL biological functions in the context of human diseases other than leukemia and cancer.

ABL1 Gene Editing Service

As a global leading biotechnological company specializing in gene editing, CRISPR/Cas9 PlatformCB is dedicated to offering comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. Based on our platform, we can help you effectively control target genes deletion, insertion or point mutation in cells and animals via CRISPR/Cas9 technology with a shorter turnaround time to accelerate your project progress.

  • ABL1 Gene Editing Cell Line Generation

With deep gene editing knowledge and extensive experience in experimental operation and data processing, we have successfully implemented ABL1 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. Tell us your needs, we are able to offer you full-length ABL1 gene editing service from strategy design to final stable cells. Our ABL1 gene editing cell line generation services include:

➢ Specific strategy design according to your needs
➢ gRNA design and synthesis
➢ Transfect the cell lines you're interested
➢ Select the high expression cells and sort monoclonal cell
➢ Validate the knockout/knockin/point mutation of ABL1 by PCR and sequencing
➢ Produce cryogenic preserved vials of stable cells and a final report

Typically, we develop CRISPR-mediated gene editing cell lines including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.

Other host cell lines available: Ba/F3, CHO, MDA-MB-453, MDA-MB-231NIH3T3, T47D, Neuro2a, MCF7, RKO, K562, RAW264.7, etc.

  • ABL1 Gene Editing Animal Model Generation

CRISPR/Cas9 PlatformCB also has extensive experience in incorporating CRISPR/Cas9 technology into animal models, which have been fully recognized by our clients. Based on our platform, we will provide you with a one-stop-shop ABL1 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price. Our ABL1 gene editing animal model generation services include:

➢ ABL1 gene conventional knockout animals
➢ ABL1 gene conditional knockout animals
➢ ABL1 point mutation animals
➢ ABL1 knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

With many years of experience in gene editing, CRISPR/Cas9 PlatformCB is devoted to providing the best CRISPR/Cas9 editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. To accelerate the achievement of your research goals, our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. If you have any questions, please feel free to contact us.

Related Products at CRISPR/Cas9 PlatformCB

CLKO-1440ABL1 KO Cell Lysate-HeLaInquiry
CSC-RT1593Human ABL1 Knockout Cell Line-HeLaInquiry


  1. Jean Y. J. Wang. The Capable ABL: What Is Its Biological Function? Molecular and Cellular Biology. 2014; 34:NO.7.
  2. William D. Bradley, Anthony J. Koleske. Regulation of cell migration and morphogenesis by Abl-family kinases: emerging mechanisms and physiological contexts. Journal of Cell Science. 2009; 122:3441-3454.
  3. Ko HS. et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc. Natl. Acad. Sci. U. S. A. 2010; 107:16691–16696.
  4. McWhirter JR & Wang JY. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol. Cell. Biol. 1991; 11:1553–1565.
  5. McWhirter JR & Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J. 1993; 12:1533–1546.
For research use only. Not intended for any clinical use.


Verification code